These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23380426)

  • 1. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers.
    Teng R; Mitchell P; Butler K
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):305-12. PubMed ID: 23380426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.
    Teng R; Mitchell PD; Butler K
    J Clin Pharm Ther; 2012 Aug; 37(4):464-8. PubMed ID: 21967645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
    Teng R; Kujacic M; Hsia J
    Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.
    Butler K; Teng R
    Curr Med Res Opin; 2011 Aug; 27(8):1585-93. PubMed ID: 21692601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
    Li H; Butler K; Yang L; Yang Z; Teng R
    Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
    Butler K; Teng R
    J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
    Teng R; Butler K
    Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
    Teng R; Mitchell P; Butler K
    Eur J Clin Pharmacol; 2013 Apr; 69(4):877-83. PubMed ID: 23093043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers.
    Teng R; Kujacic M; Hsia J
    Clin Drug Investig; 2014 Aug; 34(8):529-36. PubMed ID: 24861133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
    Teng R; Mitchell PD; Butler KA
    Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor.
    Teng R; Mitchell PD; Butler K
    J Clin Pharm Ther; 2014 Apr; 39(2):186-91. PubMed ID: 24444280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
    Teng R; Butler K
    J Clin Pharm Ther; 2012 Dec; 37(6):704-11. PubMed ID: 22747575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.
    Teng R; Butler K
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1801-8. PubMed ID: 23748750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
    Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
    Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
    Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
    Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment.
    Butler K; Teng R
    J Clin Pharmacol; 2012 Sep; 52(9):1388-98. PubMed ID: 21960668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
    Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
    Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
    Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.